1. Home
  2. HCAT vs ATYR Comparison

HCAT vs ATYR Comparison

Compare HCAT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCAT
  • ATYR
  • Stock Information
  • Founded
  • HCAT 2008
  • ATYR 2005
  • Country
  • HCAT United States
  • ATYR United States
  • Employees
  • HCAT N/A
  • ATYR N/A
  • Industry
  • HCAT Computer Software: Programming Data Processing
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HCAT Technology
  • ATYR Health Care
  • Exchange
  • HCAT Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • HCAT 318.2M
  • ATYR 330.7M
  • IPO Year
  • HCAT 2019
  • ATYR 2015
  • Fundamental
  • Price
  • HCAT $4.41
  • ATYR $3.68
  • Analyst Decision
  • HCAT Buy
  • ATYR Strong Buy
  • Analyst Count
  • HCAT 11
  • ATYR 6
  • Target Price
  • HCAT $9.27
  • ATYR $18.60
  • AVG Volume (30 Days)
  • HCAT 963.8K
  • ATYR 1.9M
  • Earning Date
  • HCAT 05-08-2025
  • ATYR 03-13-2025
  • Dividend Yield
  • HCAT N/A
  • ATYR N/A
  • EPS Growth
  • HCAT N/A
  • ATYR N/A
  • EPS
  • HCAT N/A
  • ATYR N/A
  • Revenue
  • HCAT $306,584,000.00
  • ATYR $235,000.00
  • Revenue This Year
  • HCAT $11.33
  • ATYR $1,387.23
  • Revenue Next Year
  • HCAT $9.68
  • ATYR $873.22
  • P/E Ratio
  • HCAT N/A
  • ATYR N/A
  • Revenue Growth
  • HCAT 3.60
  • ATYR N/A
  • 52 Week Low
  • HCAT $3.76
  • ATYR $1.42
  • 52 Week High
  • HCAT $9.24
  • ATYR $4.66
  • Technical
  • Relative Strength Index (RSI)
  • HCAT 42.40
  • ATYR 50.20
  • Support Level
  • HCAT $4.05
  • ATYR $2.98
  • Resistance Level
  • HCAT $4.63
  • ATYR $4.32
  • Average True Range (ATR)
  • HCAT 0.30
  • ATYR 0.36
  • MACD
  • HCAT 0.07
  • ATYR 0.03
  • Stochastic Oscillator
  • HCAT 64.57
  • ATYR 60.37

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: